PCSK9 and myocardial infarction: The Further Cardiovascular Outcomes Research with PCSK9 Inhibition Subjects with Elevated Risk (FOURIER) study demonstrated that addition of evolocumab to statin therapy produced a 15% reduction in the risk of the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina or coronary revascularization in patients with stable atherosclerotic cardiovascular disease [61].